ArticleLeukemia2020

A novel CDK9 inhibitor increases the efficacy of venetoclax (ABT-199) in multiple models of hematologic malignancies.

Darren C Phillips et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.